Exscientia plc – NASDAQ:EXAI

Add to watchlist

Market closed

Open in 2 days

+12.23%

month

+14.49%

quarter

-21.52%

year

Market Cap	633.17M
Enterprise value	214.86M

P/E	-4.62
EV/Sales	8.75
EV/EBITDA	-2.02
Price/Sales	19.88
Price/Book	0.95
PEG ratio	N/A
EPS	-1.04

Revenue	19.60M
EBITDA	-125.72M
Income	-129.32M
Revenue Q/Q	-8.17%
Revenue Y/Y	-33.86%

Profit margin	-406.22%
Oper. margin	-476.03%
Gross margin	-16.44%
EBIT margin	-476.03%
EBITDA margin	-641.21%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Exscientia plc (NASDAQ:EXAI): Profit margin
Jun 2023	3.00M	-35.97M	-1196.64%
Sep 2023	8.88M	-31.21M	-351.43%
Dec 2023	2.43M	-41.13M	-1692.8%
Mar 2024	5.29M	-21.00M	-397.11%

Exscientia Financials Estimate

Q Y

Exscientia plc (NASDAQ:EXAI): Analyst Estimates
2027	64.04M	-122.36M	-191.06%

Analysts Price target
Financials & Ratios estimates

Exscientia plc (NASDAQ:EXAI): Earnings per share (EPS)
2023-11-09	-0.42	-0.31
2024-03-21	-0.44	-0.42

Exscientia plc (NASDAQ:EXAI): Debt to assets
Jun 2023	563935000	146.66M	26.01%
Sep 2023	550131000	157.15M	28.57%
Dec 2023	510721000	154.99M	30.35%
Mar 2024	473551000	142.96M	30.19%

Exscientia plc (NASDAQ:EXAI): Cash Flow
Jun 2023	-41.28M	95.74M	-873K
Sep 2023	-34.16M	-105.46M	-919K
Dec 2023	1.22M	151.59M	-877K
Mar 2024	-30.86M	-49.85M	-842K

Exscientia alternative data

Exscientia plc (NASDAQ:EXAI): Employee count
Aug 2023	481
Sep 2023	481
Oct 2023	481
Nov 2023	481
Dec 2023	481
Jan 2024	481
Feb 2024	481
Mar 2024	483
Apr 2024	483
May 2024	483
Jun 2024	483
Jul 2024	483

Exscientia
Hedge Funds Holdings Q1 2023

15.76% -11.55%

of EXAI is owned by hedge funds

33 -17

hedge funds hold EXAI stock

19.25M -14.25M

shares is hold by hedge funds

EXAI hedge funds holdings changes

Exscientia
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 24 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 21 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 9 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

EXAI earnings call transcripts

Exscientia
Latest News

Wednesday, 20 November 2024
07:00	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery	globenewswire.com
Wednesday, 13 November 2024
09:08	Recursion and Exscientia Shareholders Approve the Proposed Combination	globenewswire.com
Wednesday, 30 October 2024
08:22	Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th	globenewswire.com
Wednesday, 16 October 2024
07:00	Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration	businesswire.com
Friday, 11 October 2024
16:30	SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI	accesswire.com
Wednesday, 9 October 2024
07:00	Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024	businesswire.com
Wednesday, 28 August 2024
12:44	Brilliant NextGen Will Expand Solutions for Builders Through its Acquisition by Private Investors	businesswire.com
Thursday, 15 August 2024
07:00	Exscientia Business Update for Second Quarter and First Half 2024	businesswire.com
Sunday, 11 August 2024
04:59	Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?	fool.com
Thursday, 8 August 2024
17:37	AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals	benzinga.com
07:39	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities	globenewswire.com
07:08	Biotech firm Recursion to buy smaller peer Exscientia for $688 million	reuters.com
Monday, 8 July 2024
10:38	3 Small-Cap Stocks With Explosive 2X Growth Potential	investorplace.com
Tuesday, 25 June 2024
11:45	Contact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc(EXAI)	accesswire.com
11:45	Exscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 - EXAI	accesswire.com
11:00	Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More	accesswire.com
11:00	Exscientia Plc Investors With Losses Are Encouraged By The Schall Law Firm To Start Communication Be Aware Of The Deadline In This Case	accesswire.com
10:30	EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm	businesswire.com
10:15	Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI	accesswire.com
10:15	Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI	accesswire.com
05:45	EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline	prnewswire.com
05:20	Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI	accesswire.com
05:15	Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI	accesswire.com
05:00	FINAL EXAI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Exscientia p.l.c. Investors to Join the Class Action Lawsuit	accesswire.com
04:20	Shareholders that lost money on Exscientia plc(EXAI) should contact Levi & Korsinsky about pending Class Action - EXAI	accesswire.com
04:20	Investors who lost money on Exscientia plc(EXAI) should contact Levi & Korsinsky about pending Class Action - EXAI	accesswire.com
04:00	EXAI Today Is The Last Day that Investors can Lead Exscientia plc Fraud Lawsuit	prnewswire.com
Monday, 24 June 2024
18:31	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c.	businesswire.com
17:40	Exscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 – EXAI	accesswire.com
17:40	Exscientia plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EXAI	accesswire.com

Ideas & Opinions

Seeking Alpha 22 May 2024

Exscientia: Drug Discovery Platform Attracting Partners And Cash
Seeking Alpha 30 Jan 2024

MoneyShow's Best Investment Ideas For 2024: Part 4
Seeking Alpha 22 Dec 2023

Doubling Down On Gain Therapeutics
Seeking Alpha 8 Dec 2023

Exscientia Looks Promising In AI-Driven Drug Development
Seeking Alpha 20 Sep 2023

Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy
Seeking Alpha 1 Aug 2023

Exscientia Is Worth The AI-Driven Speculation
Seeking Alpha 18 May 2023

Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision Medicine
Seeking Alpha 17 May 2023

Pardes Biosciences Seeking Strategic Alternatives
Seeking Alpha 17 Feb 2023

Exscientia: Direct Exposure To AI Integration To Drug Discovery, Development
Seeking Alpha 22 Jan 2023

Schrodinger: Solving The Critical Need For AI/ML In The Biopharma Industry

Frequently Asked Questions (FAQ)

When is Exscientia's next earnings date?

Unfortunately, Exscientia's (EXAI) next earnings date is currently unknown.
Does Exscientia pay dividends?

No, Exscientia does not pay dividends.
How much money does Exscientia make?

Exscientia has a market capitalization of 633.17M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 38.97% to 20.08M US dollars. Exscientia made a loss 145.96M US dollars in net income (profit) last year or -$0.42 on an earnings per share basis.
What is Exscientia's stock symbol?

Exscientia plc is traded on the NASDAQ under the ticker symbol "EXAI".
What is Exscientia's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Exscientia?

Shares of Exscientia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Exscientia have?

As Jul 2024, Exscientia employs 483 workers.
When Exscientia went public?

Exscientia plc is publicly traded company for more then 3 years since IPO on 1 Oct 2021.
What is Exscientia's official website?

The official website for Exscientia is exscientia.ai.
How can i contact Exscientia?

Exscientia can be reached via phone at +44 1865 818941.

Exscientia plc

exscientia.ai

Exchange:

NASDAQ

Full time employees:

483

Industry:

Biotechnology

Sector:

Healthcare

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

+44 1865 818941

The SchrOedinger Building
Oxford, OX4 4GE

CIK: 0001865408
ISIN: US30223G1022
CUSIP: 30223G102